December 21, 2021
Biogen will slash the US price of its Alzheimer’s drug Aduhelm (aducanumab) by around half to reduce patients’ out-of-pocket expenses and potential financial implications for the healthcare system, the company said on December 20. The near 50% reduction on Aduhelm’s...read more